Total Valuation
PTC Therapeutics has a market cap or net worth of €4.92B. The enterprise value is €5.97K.
Market Cap€4.92B
Enterprise Value€5.97K
Share Statistics
PTC Therapeutics has 83,460,800 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding83,460,800
Owned by Insiders1.49%
Owned by Institutions0.39%
Financial Efficiency
PTC Therapeutics’s return on equity (ROE) is -3.32 and return on invested capital (ROIC) is 37.39%.
Return on Equity (ROE)-3.32
Return on Assets (ROA)0.23
Return on Invested Capital (ROIC)37.39%
Return on Capital Employed (ROCE)0.44
Revenue Per Employee1.75M
Profits Per Employee688.84K
Employee Count991
Asset Turnover0.59
Inventory Turnover0.90
Valuation Ratios
The current PE Ratio of PTC Therapeutics is ―. PTC Therapeutics’s PEG ratio is -0.03.
PE Ratio―
PS Ratio3.49
PB Ratio-29.43
Price to Fair Value-29.43
Price to FCF14.69
Price to Operating Cash Flow-185.07
PEG Ratio-0.03
Income Statement
In the last 12 months, PTC Therapeutics had revenue of 1.73B and earned 682.64M in profits. Earnings per share was 8.58.
Revenue1.73B
Gross Profit1.66B
Operating Income856.51M
Pretax Income696.62M
Net Income682.64M
EBITDA887.66M
Earnings Per Share (EPS)8.58
Cash Flow
In the last 12 months, operating cash flow was -30.50M and capital expenditures -302.05M, giving a free cash flow of -332.56M billion.
Operating Cash Flow-30.50M
Free Cash Flow-332.56M
Free Cash Flow per Share-3.98
Dividends & Yields
PTC Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.64
52-Week Price Change43.99%
50-Day Moving Average67.35
200-Day Moving Average62.27
Relative Strength Index (RSI)48.69
Average Volume (3m)7.00
Important Dates
PTC Therapeutics upcoming earnings date is Oct 22, 2026, After Close (Confirmed).
Last Earnings DateJul 30, 2026
Next Earnings DateOct 22, 2026
Ex-Dividend Date―
Financial Position
PTC Therapeutics as a current ratio of 2.35, with Debt / Equity ratio of -421.18%
Current Ratio2.35
Quick Ratio2.27
Debt to Market Cap0.07
Net Debt to EBITDA-0.55
Interest Coverage Ratio5.63
Taxes
In the past 12 months, PTC Therapeutics has paid 13.97M in taxes.
Income Tax13.97M
Effective Tax Rate0.02
Enterprise Valuation
PTC Therapeutics EV to EBITDA ratio is 6.25, with an EV/FCF ratio of 13.50.
EV to Sales3.21
EV to EBITDA6.25
EV to Free Cash Flow13.50
EV to Operating Cash Flow7.80
Balance Sheet
PTC Therapeutics has €2.23B in cash and marketable securities with €696.47M in debt, giving a net cash position of €1.53B billion.
Cash & Marketable Securities€2.23B
Total Debt€696.47M
Net Cash€1.53B
Net Cash Per Share€18.36
Tangible Book Value Per Share-€8.50
Margins
Gross margin is 82.14%, with operating margin of 49.49%, and net profit margin of 39.44%.
Gross Margin82.14%
Operating Margin49.49%
Pretax Margin40.25%
Net Profit Margin39.44%
EBITDA Margin51.29%
EBIT Margin49.05%
Analyst Forecast
The average price target for PTC Therapeutics is €85.27, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target€85.27
Price Target Upside26.51% Upside
Analyst ConsensusStrong Buy
Analyst Count12
Revenue Growth Forecast-47.71%
EPS Growth Forecast-105.52%